Anzeige
Mehr »
Login
Montag, 31.03.2025 Börsentäglich über 12.000 News von 695 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40EFY | ISIN: US7665597024 | Ticker-Symbol: RI2
Tradegate
31.03.25
15:38 Uhr
15,800 Euro
-0,700
-4,24 %
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
RIGEL PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
RIGEL PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
16,40016,80022:04
16,30016,90022:00

Aktuelle News zur RIGEL PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoRigel settles patent litigation regarding its immune thrombocytopenia treatment3
DoRigel Pharma Settles Tavalisse Patent Litigation With Annora Pharma 228WASHINGTON (dpa-AFX) - Rigel Pharmaceuticals, Inc. (RIGL) Thursday announced that it has entered into a settlement agreement with Annora Pharma Private Ltd., Hetero Labs Ltd., and Hetero USA...
► Artikel lesen
DoRIGEL PHARMACEUTICALS INC - 8-K, Current Report3
DoRigel settles patent litigation over TAVALISSE treatment2
10.03.Rigel Pharmaceuticals erweitert Vorstand um Onkologie-Experten1
10.03.Rigel Pharmaceuticals adds oncology expert to board2
06.03.Citi lifts Rigel stock price target to $55, maintains Buy rating2
06.03.Al Seer Marine completes first stage of expansion with delivery of Tabit and Rigel MR tankers1
RIGEL PHARMACEUTICALS Aktie jetzt für 0€ handeln
05.03.Rigel Pharmaceuticals (NASDAQ:RIGL) Posts Earnings Results, Beats Estimates By $0.50 EPS1
05.03.Cantor Fitzgerald maintains Rigel stock Neutral with $20 target12
05.03.Rigel Pharmaceuticals stock holds Buy rating, $57 target10
04.03.Rigel Pharmaceuticals Inc. Q4 Profit Advances338WASHINGTON (dpa-AFX) - Rigel Pharmaceuticals Inc. (RIGL) released earnings for its fourth quarter that increased from the same period last yearThe company's bottom line came in at $14.34 million...
► Artikel lesen
04.03.Rigel Pharmaceuticals GAAP EPS of $0.80 beats by $0.18, revenue of $57.6M in-line4
04.03.Rigel Pharmaceuticals, Inc.: Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update372Fourth quarter 2024 total revenue of approximately $57.6 million, which includes TAVALISSE® net product sales of $31.0 million, REZLIDHIA® net product sales of...
► Artikel lesen
04.03.RIGEL PHARMACEUTICALS INC - 8-K, Current Report1
04.03.RIGEL PHARMACEUTICALS INC - 10-K, Annual Report2
25.02.Should You Add RIGL Stock to Your Portfolio Pre-Q4 Earnings?4
24.02.RIGL Stock Surges 41.4% in a Year: Time to Buy or Sell?2
22.01.Rigel Pharmaceuticals' (RIGL) "Buy" Rating Reiterated at HC Wainwright2
22.01.Rigel's fostamatinib enters Phase 1 trial for sickle cell treatment2
Seite:  Weiter >>
56 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1